	US 11,912,761 B2
	IL-1β neutralizing human monoclonal antibodies
Cheng-I Wang, Singapore (SG); Angeline Goh, Singapore (SG); Siok Ping Yeo, Singapore (SG); Alessandra Rosa Mortellaro, Singapore (SG); Subhra Kumar Biswas, Singapore (SG); Florent Ginhoux, Singapore (SG); and Pingyu Zhong, Singapore (SG)
Assigned to Agency for Science, Technology and Research, Singapore (SG)
Filed by Agency for Science, Technology and Research, Singapore (SG)
Filed on Jan. 15, 2021, as Appl. No. 17/150,689.
Application 17/150,689 is a division of application No. 16/192,537, filed on Nov. 15, 2018, granted, now 10,919,962.
Application 16/192,537 is a division of application No. 14/378,442, granted, now 10,167,335, issued on Jan. 1, 2019, previously published as PCT/SG2013/000057, filed on Feb. 13, 2013.
Claims priority of application No. 201201007-0 (SG), filed on Feb. 13, 2012.
Prior Publication US 2021/0155685 A1, May 27, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/245 (2013.01) [A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C07K 2317/10 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

18 Claims

1. A method of inhibiting overexpression of IL-1β in a subject in need thereof, comprising administering to the subject an effective amount of an isolated monoclonal antibody which specifically binds to IL-1β, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises:

(i) Complementarity Determining Regions (CDRs) according to the Kabat numbering convention of a light chain comprising the amino acid sequence of SEQ ID NO: 17; and

(ii) CDRs according to the Kabat numbering convention of a heavy chain comprising the amino acid sequence of SEQ ID NO: 14,

wherein the subject has an autoimmune disease.